ESBATech Company
Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.
Headquarters:
Schlieren, Zurich, Switzerland, Europe
Founded Date:
1998-01-01
Industry:
Cell, Gene & Biologics Therapeutics
Employee Number:
51-100
Super Industry:
Biopharma & Life Science Tools
Phone Number:
+41447334990
Investors:
BioMedPartners, Clarus Ventures, Novartis Venture Fund, SV Health Investors, VI Partners
Ipo Status:
private
City:
Schlieren
Region:
Zurich
Country:
Switzerland
Founders:
Dominik Escher